Soleno Therapeutics, Inc. (SLNO)
$
75.62
-0.15 (-0.20%)
Key metrics
Financial statements
Free cash flow per share
-1.9388
Market cap
3.9 Billion
Price to sales ratio
0
Debt to equity
0.0127
Current ratio
19.6373
Income quality
0.4506
Average inventory
0
ROE
-0.7752
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Soleno Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapeutics aimed at treating rare diseases. The company incurred an income tax expense of $0.00 indicating its tax obligations. Its lead candidate, Diazoxide Choline Controlled-Release, is a once-daily oral tablet designed for the treatment of Prader-Willi Syndrome, which is currently being evaluated in an ongoing Phase III clinical development program. The earnings per share (EPS) is reported at -$4.38 reflecting the company's profitability on a per-share basis, while the diluted EPS is -$4.38 accounting for potential share dilution. Furthermore, the net income ratio stands at 0.00 which highlights the company's profitability margin. The gross profit amounts to $0.00 emphasizing the company's earnings from core operations. Soleno Therapeutics, Inc. was formerly known as Capnia, Inc. and transitioned to its current name in May 2017. Incorporated in 1999, the company is headquartered in Redwood City, California. The stock is affordable at $75.62 making it an attractive option for budget-conscious investors. With an average trading volume of 1,312,759.00 the stock exhibits moderate liquidity, which can be appealing to various types of investors. With a market capitalization of $3,810,786,718.00 the company is classified as a small-cap player within the pharma sector. It is a key player in the Biotechnology industry, contributing significantly to the overall market landscape. As a member of the Healthcare sector, Soleno Therapeutics, Inc. is driving innovation and growth, positioning itself to make impactful advancements in the field of rare disease therapeutics.
Is Soleno Therapeutics, Inc. (SLNO) a good investment?
Investing in Soleno Therapeutics, Inc. (SLNO) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as C, with a Bearish outlook. Always conduct your own research before investing.
What is Soleno Therapeutics, Inc. (SLNO)'s stock forecast?
Analysts predict Soleno Therapeutics, Inc. stock to fluctuate between $36.93 (low) and $80.99 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Soleno Therapeutics, Inc.'s market capitalization?
As of 2025-05-30, Soleno Therapeutics, Inc.'s market cap is $3,810,786,718, based on 50,393,900 outstanding shares.
How does Soleno Therapeutics, Inc. compare to competitors like Eli Lilly & Co.?
Compared to Eli Lilly & Co., Soleno Therapeutics, Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy Soleno Therapeutics, Inc. (SLNO) stock?
To buy Soleno Therapeutics, Inc. (SLNO) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for SLNO. Place an order (Market, Limit, etc.).
What is the best time to invest in Soleno Therapeutics, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bearish trend based on economic conditions and company performance.
Has Soleno Therapeutics, Inc. stock ever split?
Soleno Therapeutics, Inc.'s last stock split was 1:15 on 2022-08-26.
How did Soleno Therapeutics, Inc. perform in the last earnings report?
Revenue: $0 | EPS: -$4.38 | Growth: 85.59%.
Where can I find Soleno Therapeutics, Inc.'s investor relations reports?
Visit https://soleno.life/investor-relations for detailed financial reports.
Where can I find historical stock prices for Soleno Therapeutics, Inc.?
You can explore historical data from here
What is the all-time high and low for Soleno Therapeutics, Inc. stock?
All-time high: $80.99 (2025-05-08) | All-time low: $0.85 (2022-12-15).
What are the key trends affecting Soleno Therapeutics, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
globenewswire.com
8 days ago
REDWOOD CITY, Calif., May 22, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that Soleno's Marketing Authorization Application (MAA) seeking regulatory approval of Diazoxide Choline Prolonged-Release Tablets (previously referred to as DCCR) for the treatment of adults and children four years and older with Prader-Willi syndrome (PWS) who have hyperphagia had been validated by the European Medicines Agency (EMA).
globenewswire.com
10 days ago
REDWOOD CITY, Calif., May 20, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced data presented from its clinical development program of VYKAT™ XR (diazoxide choline) extended-release tablets, previously referred to as DCCR, at the Pediatric Endocrine Society (PES) Annual Meeting 2025, which was held May 15-18 in National Harbor, Maryland, USA. The presentation showed that resumption of VYKAT XR treatment in participants with PWS following a 16-week randomized withdrawal was associated with significant improvements in both hyperphagia and behavioral symptoms.
seekingalpha.com
23 days ago
Soleno Therapeutics, Inc. (NASDAQ:SLNO ) Q1 2025 Earnings Conference Call May 7, 2025 4:30 PM ET Company Participants Brian Ritchie - LifeSci Advisors Anish Bhatnagar - Chief Executive Officer Meredith Manning - Chief Commercial Officer Jim Mackaness - Chief Financial Officer Conference Call Participants Yasmeen Rahimi - Piper Sandler Debjit Chattopadhyay - Guggenheim Securities Kristen Kluska - Cantor Leland Gershell - Oppenheimer Brian Skorney - Baird James Condulis - Stifel Myriam Belghiti - LifeSci Capital Yale Jen - Laidlaw Operator Greetings, and welcome to the Soleno Therapeutics First Quarter 2025 Earnings Conference Call. At this time, note that all participants are in a listen-only mode.
globenewswire.com
23 days ago
REDWOOD CITY, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today provided an update on the U.S. launch of VYKATTM XR and reported financial results for the first quarter ended March 31, 2025.
zacks.com
25 days ago
Soleno Therapeutics (SLNO) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
globenewswire.com
a month ago
REDWOOD CITY, Calif., April 23, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that it will report its first quarter 2025 financial results, as well as operational highlights, after the close of the U.S. financial markets on Wednesday, May 7, 2025. The Company will host a conference call and webcast at 4:30 PM Eastern Time to discuss the results and provide an update on business operations.
globenewswire.com
2 months ago
REDWOOD CITY, Calif., April 14, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced the U.S. commercial availability of VYKAT™ XR (diazoxide choline) extended-release tablets, the company's treatment for hyperphagia in patients four years of age and older with Prader-Willi syndrome (PWS), which was approved by the U.S. Food and Drug Administration (FDA) on March 26, 2025.
zacks.com
2 months ago
Soleno's shares soar in the premarket hours following the FDA approval of Vykat XR (diazoxide choline) for treating hyperphagia in PWS patients.
benzinga.com
2 months ago
The U.S. Food and Drug Administration (FDA) on Wednesday approved Soleno Therapeutics, Inc.'s SLNO Vykat XR (diazoxide choline) extended-release tablets, previously referred to as DCCR, for hyperphagia in adults and children 4 years of age and older with Prader-Willi syndrome (PWS).
globenewswire.com
2 months ago
First approved therapy to address hyperphagia in individuals with Prader-Willi syndrome Management to host conference call and webcast today, March 26 th , at 5:30pm ET REDWOOD CITY, Calif., March 26, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has approved VYKAT XR (diazoxide choline) extended-release tablets, previously referred to as DCCR, for the treatment of hyperphagia in adults and children 4 years of age and older with Prader-Willi syndrome (PWS).
See all news
